Advertisement

“Danshen” the Night Away

Fatal Forty DDI: Salvia miltiorrhiza, warfarin, CYP2C9, CYP1A2
  • Tara C. CareyEmail author
  • Kirk Lalwani

Abstract

This case discusses a mixed pharmacodynamic and pharmacokinetic drug interaction between warfarin and danshen resulting in increased anticoagulation.

Keywords

Pharmacodynamic Pharmacokinetic Inhibitor Inhibition Danshen Danshensu Tanshinone I Tanshinone IIA Cryptotanshinone Protocatechuic aldehyde Protocatechuic acid Salvianolic acid B Salvia miltiorrhiza Herb Herb-drug interaction Anticoagulation Warfarin Coumadin International Normalized Ratio INR Pharmacokinetic Pharmacodynamics Digoxin Bioavailability Elimination Albumin Platelet Platelet adhesion Platelet aggregation Protein binding Potentiation 

References

  1. 1.
    Kam PC, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia. 2002;57(11):1083–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheng TO. Warfarin danshen interaction. Ann Thorac Surg. 1999;67(3):894.PubMedCrossRefGoogle Scholar
  3. 3.
    Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother. 2001;35(4):501–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Izzat MB, Yim AP, El-Zufari MH. A taste of Chinese medicine! Ann Thorac Surg. 1998;66(3):941–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Tam LS, Chan TY, Leung WK, et al. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust N Z J Med. 1995;25(3):258.PubMedCrossRefGoogle Scholar
  6. 6.
    Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by ‘danshen’. J Intern Med. 1997;241(4):337–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan K, Lo AC, Yeung JH, et al. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol. 1995;47(5):402–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):8S–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41(9):1633–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang CM, Cheung WY, Lee PM, et al. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine. 2010;17:868–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Qiu F, Zhang R, Sun J, et al. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos. 2008;36(7):1308–14. Epub 2008 Apr 14.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45(12):1345–59.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Anesthesiology and Perioperative MedicineBrigham and Women’s HospitalBostonUSA
  2. 2.Department of Anesthesiology & Perioperative MedicineOregon Health and Science UniversityPortlandUSA

Personalised recommendations